Kei­th Dion­ne's Cas­ma lines up a $50M ven­ture round to con­tin­ue the pre­clin­i­cal work on a cel­lu­lar re­cy­cling pro­gram

Two years af­ter launch­ing out of Third Rock’s in­cu­ba­tor, Cas­ma Ther­a­peu­tics has land­ed a $50 mil­lion Se­ries B for pre­clin­i­cal de­vel­op­ment of its mus­cu­lar dy­s­tro­phy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER